logo-loader
viewAmryt Pharma PLC

Amryt Pharma 'doing very well with strong cash and recurring revenues'

Amryt Pharma PLC's (LON:AMYT) Dr Joe Wiley tells Proactive London's Andrew Scott the business is well capitalised and resilient.

Pro forma revenues of the newly enlarged group were up 13.1% at US$154.1mln in the year just gone as it reported that a strong end to 2019 carried on into 2020.

Quick facts: Amryt Pharma PLC

Price: 210 GBX

AIM:AMYT
Market: AIM
Market Cap: £332.85 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: Sterling six week lows and further lockdown woes

The FTSE is higher as we head into early afternoon trade with Sterling still loitering around that six week low and news from drug giant AstraZeneca PLC (LON:AZN) that it is putting its coronavirus vaccine trials on hold after a patient participating got poorly which has triggered...

1 week, 3 days ago

2 min read